Evidence map›Paper›PMID 26564428›Full record

ReviewTransboundary and emerging diseases2017

Review: Capripoxvirus Diseases: Current Status and Opportunities for Control.

E S M Tuppurainen, E H Venter, J L Shisler, G Gari, G A Mekonnen, N Juleff, N A Lyons, K De Clercq, C Upton, T R Bowden and 2 more

Open access · hybridAbstract readReview
In one paragraph

Review in Transboundary and emerging diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 213 papers.

0numbers the graph read from it
0cells of the map it votes in
213citing papers in PubMed
6.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

213 citing papers in PubMed, 384 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

153 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 11 institutions in 9 countries.

E S M TuppurainenDepartment of Veterinary Biosciences, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland.
E H VenterDepartment of Veterinary Tropical Diseases, University of Pretoria, Pretoria, South Africa.
J L ShislerDepartment of Microbiology, University of Illinois, Urbana, IL, USA.
G GariNational Animal Health Diagnostic and Investigation Center (NAHDIC), Sebeta, Ethiopia.
G A MekonnenNational Animal Health Diagnostic and Investigation Center (NAHDIC), Sebeta, Ethiopia.
N JuleffBill & Melinda Gates Foundation, Seattle, WA, USA.
N A LyonsThe Pirbright Institute, Pirbright, UK.
K De ClercqCODA-CERVA, Vesicular and Exotic Diseases Unit, Uccle, Belgium.
C UptonDepartment of Biochemistry and Microbiology, University of Victoria, Victoria, BC, Canada.
T R BowdenCSIRO, Health & Biosecurity Flagship, Australian Animal Health Laboratory, Geelong, Vic., Australia.
S BabiukCanadian Food Inspection Agency, National Centre for Foreign Animal Disease, Winnipeg, WA, Canada.
L A BabiukUniversity of Alberta, Edmonton, AB, Canada.
National Institute of Animal Science · KRAustralian Centre for Disease Preparedness · AUBill & Melinda Gates Foundation · USCanadian Food Inspection Agency · CAFood and Agriculture Organization of the United Nations · ITUniversity of Alberta · CAUniversity of Helsinki · FIUniversity of Illinois Urbana-Champaign · USUniversity of Pretoria · ZAUniversity of Victoria · CAVeterinary and Agrochemical Research Centre · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lumpy skin disease, sheeppox and goatpox are high-impact diseases of domestic ruminants with a devastating effect on cattle, sheep and goat farming industries in endemic regions. In this article, we review the current geographical distribution, economic impact of an outbreak, epidemiology, transmission and immunity of capripoxvirus. The special focus of the article is to scrutinize the use of currently available vaccines to investigate the resource needs and challenges that will have to be overcome to improve disease control and eradication, and progress on the development of safer and more effective vaccines. In addition, field evaluation of the efficacy of the vaccines and the genomic database available for poxviruses are discussed.

Indexed as

CapripoxvirusAnimalsDisease OutbreaksPoxviridae Infectionscontrolgoatpoximmunitylumpy skin diseasesheeppoxvaccines

Identifiers

PMID26564428
PMCPMC5434826
OpenAlexW2238899646

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.